Reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer

Journal of Korean Medical Science

Volumn 20, Issue 5, 2005, Pages 806-810

  Jee, Hyun Kim ^a   Oh, Do Youn ^a   Yu, Jung Kim ^a   Sae, Won Han ^a   Choi, In Sil ^a   Kim, Dong Wan ^a   Im, Seock Ah ^a   Kim, Tae You ^a   Lee, Jong Seok ^a   Heo, Dae Seog ^a   Bang, Yung Jue ^a   Noe, Kyeong Kim ^a  

^a Seoul National University   (South Korea)

Author keywords

Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Folfox protocol

Indexed keywords

EID: 27744452928     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.2005.20.5.806     Document Type: Article

References (23)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26.
2. Enzinger PC, Mayer RJ. Gastrointestinal cancer in older patients. Semin Oncol 2004; 31: 206-19.
3. Headquarter of Korea Central Cancer Registry. 2002 Annual Report of the Korea Central Cancer Registry. Available from: URL: http://www.ncc.re.kr. [Accessed 10 May 2005]
4. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939-44.
5. Glimelius B, Hoffman K, Graf W, Pahlman L, Sjoden PO. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Cancer 1994; 73: 556-62.
6. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
7. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
8. Trimble EL, Carter CL, Cain D, Freidlin B, Ungerleider RS, Friedman MA. Representation of older patients in cancer treatment trials. Cancer 1994; 74 (Suppl 7): 2208-14.
9. Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, Housman MG, Escarce JJ. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003; 21: 1383-9.
10. National Cancer Institute: Guidelines for reporting of adverse drug reactions. Bethesda, MD, National Cancer Institute, Division of Cancer Treatment, 1998.
11. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
12. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998: 25 (2 Suppl 5): 4-12.
13. Chiara S, Nobile MT, Vincenti M, Lionetto R, Gozza A, Barzaqcchi MC, Sanguineti O, Repetto L, Rosso R. Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol 1998; 42: 336-40.
14. Kohne CH, Grothey A, Bokemeyer C, Bontke N, Aapro M. Chemotherapy in elderly patients with colorectal cancer. Ann Oncol 2001; 12: 435-42.
15. Magne N, Francois E, Broisin L, Guardiolo E, Ramaioli A, Ferrero JM, Namer M. Palliative 5-fluorouracil-based chemotherapy for advanced colorectal cancer in the elderly: results of 10-year experience. Am J Clin Oncol 2002; 25: 126-30.
16. Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999; 17: 2412-8.
17. Berretta M, Buonadonna A, Rupolo M, Frustaci S, Bearz A, Sorio R, Freschi A, Scalone S, Michieli M, Spina M, Tirelli U, Colussi AM, Cartei G. Comparison between elderly and non-elderly patients, of efficacy and tolerability of FOLFOX2 schedule in advanced colorectal cancer. Proc Am Soc Clin Oncol 2001; 20: A2195 (abstr).
18. Mattioli R, Massacesi C, Recchia F, Marcucci F, Cappelletti C, Imperatori L, Pilone A, Rocchi M, Cesta A, Laici G, Bonsignori M, Lippe P. High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann Oncol 2005; 16: 1147-51.
19. Haller DG. Safety of oxaliplatin in the treatment of colorectal cancer. Oncology (Huntingt) 2000; 14 (12 Suppl 11): 15-20.
20. Sundararajan V, Grann VR, Jacobson JS, Ahsan H, Neugut AI. Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: a population-based study. Cancer J 2001; 7: 213-8.
21. Kim HJ, Min WS, Park YH, Park SJ, Lee JW, Jin JY, Han CH, Park CW, Kim CC. Induction chemotherapy for patients with acute myeloid leukemia aged over 60 years. Korean J Hematol 2003; 38: 228-33.
22. Choi JH, Ahn MJ, Ki MR, Oh HS, Lee YY, Choi IY, Kim IS. Clinical prognostic factors and treatment outcome of aggressive non-Hodgkin's lymphoma in elderly patients. Cancer Res Treat 2001; 33: 324-8.
23. Ryu JW, Ryu SB, Park YI. M-VAC chemotherapy for bladder cancer in elderly. Korean J Urol 1999; 40: 1274-8.